Prerpints.org logo
Preprint
Review

The Bidirectional Association Between Periodontitis and COVID-19: A Review of Current Evidence

Altmetrics

Downloads

214

Views

67

Comments

0

This version is not peer-reviewed

Preprints on COVID-19 and SARS-CoV-2

Submitted:

22 May 2023

Posted:

23 May 2023

You are already at the latest version

Alerts
Abstract
The COVID-19 pandemic has brought marked changes worldwide to the management of airborne infectious diseases. It sparked the development of the SARS-CoV-2 vaccine and pharmacotherapeutics to prevent infection and increase the survival rate during the acute viral phase and the comorbidities associated with COVID-19. Periodontal disease may increase the morbidity and perhaps the mortality of a COVID-19 infection. However, the molecular interaction between periodontitis and COVID-19 infection remains undetermined. A potential pathogenic co-morbidity may involve periodontal pathogenic release of destructive cytokines in the highly inflamed connective tissue and risk for COVID-19. Additional biomarkers such as C-reactive proteins appear to play a role for risk and pathogenesis of COVID-19. The potential of herpesviruses, especially as it is related to aggressive periodontitis may also be a comorbidity for COVID-19. This paper reviews available evidence on the bidirectional association between periodontitis and COVID-19.
Keywords: 
Subject: Medicine and Pharmacology  -   Dentistry and Oral Surgery

1. Introduction

On March 11, 2020, the World Health Organization declared a global coronavirus disease of 2019 (COVID-19) pandemic [1]. The COVID-19 pandemic is caused by the newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). When an infected individual speaks, sneezes, coughs, sings, or breathes; SARS-CoV-2 can spread from their mouth or nose via microscopic droplet particles. COVID-19 complications are more likely in older individuals and those with underlying medical disorders like cancers, diabetes, cardiovascular diseases, or chronic respiratory diseases [2,3,4]. These comorbidities are also associated with periodontitis [5,6,7,8,9].
According to the American Dental Association, periodontitis is an inflammatory disease of bacterial etiology resulting in the loss of periodontal tissue attachment and alveolar bone [10]. It is among the most widespread conditions affecting the oral cavity and continues to be a worldwide health concern. Periodontal disease must be treated quickly since it may impact the patient’s general health [11].
The potential pathway for the relationship between periodontal health and systemic health includes periodontitis associated putative pathogenic oral microbiota, overexpression of local and systemic pro-inflammatory destructive cytokine [12,13]. In addition, the reactivation of latent systemic herpesvirus infections has been associated with the onset of aggressive periodontal disease [14]. Active human cytomegalovirus infection has been detected in deep periodontal pockets in localized aggressive periodontitis patients [15]. Therefore, at least several viruses have recently been implicated in potentiating periodontal infections. It is plausible that this herpetic viral coinfection may have an additive effect on COVID-19 risk.
Research has shown that SARS-CoV-2 enters the body through ACE-2 receptors on the surface of host cells. ACE-2 receptor expression related to systemic conditions like hypertension, chronic obstructive pulmonary disease (COPD), hepatic disorders, renal dysfunctions or diabetes, can facilitate viral entrance into host cells [16]. The primary function of the angiotensin-converting enzyme (ACE) in the renin-angiotensin system (RAS) is to inhibit the levels of angiotensin II and raise the levels of angiotensin I-7, this activates molecular signaling pathways associated with tissue damage and inflammation [17].
Studies have shown that ACE-2 receptors in human pulmonary epithelial cells are upregulated by periodontopathic bacteria [18]. Additionally, the ACE-2 receptors found on periodontal tissue cells allow the virus to enter and circulate throughout the body. When compared to the lungs, the oral cavity expresses many ACE-2 receptors [19,20,21]. SARS-CoV-2 found in dental biofilm and periodontal tissues showed that the periodontal and oral environments may contribute to COVID-19 infectivity [22]. Additionally, the blocking of SARS-CoV-2 invasion via the blocking the ACE-2 receptors and decreasing transmembrane serine protease 2 (TMPRSS2), may also prevent SARS-CoV-2 infection of the periodontal epithelium [23].

2. Effect of periodontitis on SARS-CoV-2 entry molecules

For a person to be vulnerable to the SARS-CoV-2, the virus must first successfully enter the host cells. There are multiple pathways by which SARS-CoV-2 can enter human cells [24]. These pathways involve the virus targeting these SARS-CoV-2 entry molecules present on the host cells. These molecules include ACE-2 receptors, TMPRSS2, and furin. These SARS-CoV-2 entry molecules promote virus entry into the host cells and are determinants of COVID-19 infection [25,26].
SARS-CoV-2 entry molecules are present on the dorsal tongue and gingiva. Saliva and tongue coatings were sampled to determine the presence of these molecules in the oral cavity. Immunohistochemical studies detected ACE-2 receptors in the stratified squamous epithelium of the dorsal tongue and gingiva. The ACE-2-positive cells were 2.2% of the oral tissue, of which 92% were epithelial cells [27]. Similarly, TMPRSS2 was found in the stratified squamous epithelium of the gingival keratinized surface layer. TMPRSS2 was also detected in saliva and tongue coatings via Western blot. Furin was localized mainly in the lower layers of the stratified squamous epithelium. Furin was detected in the saliva but not in tongue-coating samples [25,26]. ACE-2, TMPRSS2, and furin mRNA expression were present in taste bud-derived cultured cells, and this was further supported by immunofluorescence observations [27].
The periodontal pocket epithelium may be an entry point for SARS-CoV-2, because it expresses both ACE-2 receptors and TMPRSS2. In addition, the pocket epithelium cell layer may be thin and exhibit microulcerations; thus, increasing the risk of SARS-CoV-2 entry and infection [28].
Other factors such as salivary levels of ACE-2 were found to increase with the severity of the periodontitis and were positively associated with the alveolar bone loss [29].
ACE-2 receptors were identified in 2003 as the entry receptor for SARS-CoV. SARS-CoV-2 shares 79.5% genome sequence identity with SARS-CoV [30]. Thus, SARS-CoV-2 and SARS-CoV can enter the host cell via the same receptor. Organ dysfunction caused by SARS-CoV-2, such as acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury, and acute hepatic injury, is common in severe cases. However, the overall mortality rate of COVID-19 caused by SARS-CoV-2 was lower than SARS and MERS [30].
SARS-CoV-2 entry into cells is particular to ACE-2 expressing cells; other coronavirus receptors like aminopeptidase N and dipeptidyl peptidase (DPP4) do not have the same effect [30]. The binding affinity of the SARS-CoV-2 spike glycoprotein to the ACE-2 receptor is 10–20 fold higher than that of SARS-CoV [31,32]. The ACE-2 receptor in the host cell membrane and furin cleavage site of SARS-CoV-2 allowed the virus to invade the host cells [33,34,35]. ACE-2 and TMPRSS2 are also expressed in various organs throughout the body, including the lung, heart, pancreas, kidney, bladder, small intestine, and skin [25,26].
TMPRSS2 is another essential factor that facilitates SARS-COV-2 entry and infectivity. TMPRSS2 cleaves viral spike protein and is a cofactor to ACE-2 for viral entry. It is a crucial serine protease for SARS-CoV-2 invasion [36].
In a gene expression analysis study of TMPRSS2, the Gene Expression Omnibus (GEO) dataset analysis in an experimentally induced periodontitis model showed increased TMPRSS2 expression in gingiva with periodontitis. The keratinocyte cell membrane of the periodontitis gingiva is strongly stained immunohistochemically for TMPRSS2 [13].
SARS-CoV-2 spike protein binds the cell membrane when activated by specific cellular enzymes like furin [28]. Furin cleaves the glycoprotein viral envelop, enhancing the viral fusion with the host cell membrane. Genomic characterization revealed that the furin enzyme might activate the specific site of the SARS-CoV-2 spike protein [27]. The furin cleavage site in the SARS-CoV-2 spike protein facilitates the virus-cell fusion [37]. This furin cleavage site is not found in SARS-CoV. Single-cell sequence dataset analysis found furin expression in potential target organs such as the lung, nose, heart, intestine, colon, rectum, and ileum [27]. Among the furin-expressing cells analyzed, epithelial cells make up more than 55% [27]. Sites with active periodontitis exhibit elevated expression of furin and cathepsin L proteases and may have an increased risk for virus binding and tissue infection [38].

3. Clinical studies associating periodontitis and COVID-19

Periodontitis can increase complications and the risk of death from COVID-19 (Table 1), and COVID-19 infection can aggravate periodontitis (Table 2). Research studies (Table 1 and Table 2) in the form of prospective studies, retrospective studies, cross-sectional studies, longitudinal studies, case-control studies, case series, and case reports regarding this bidirectional relationship have been published. The statistical significance and the risk of morbidity and mortality were reported in these studies.

3.1. Periodontitis associated with COVID-19 Severity

Studies (Table 1) reported that periodontitis is significantly associated with COVID-19 complications, the severity of COVID-19 symptoms, the need for assisted ventilation, ICU admissions, and death [39,40,41,42,43,44]. Furthermore, COVID-19 patients with non-treated stage 2–4 periodontitis were significantly associated with an increased level of inflammatory biomarkers of COVID-19, such as D-dimer and ferritin [40]. Subjects with the moderate form of COVID-19 had more severe periodontitis when compared to those with the mild form of COVID-19 [43]. These collective studies appear to clearly demonstrate a biologic gradient for periodontitis severity and risk for progressive COVID-19. On the contrary, one study reported no statistical significance associated with COVID-19 and periodontitis; this could be attributed to the limitations of self-reported data on periodontal disease [45].
Of significance, COVID-19 patients with periodontitis have a high risk of mortality from COVID-19 and a medium risk of COVID-19 complications, ICU admission, and assisted ventilation [46]. There was a suggestive risk of periodontal disease in the obese, presenting a higher incidence of hospitalization and mortality from COVID-19 [47]. In patients with painful, bleeding gums and loose teeth, there was a suggestive risk of hospitalization and mortality following COVID-19 infection [48].

3.2. Effects of COVID-19 on periodontitis

COVID-19 can exacerbate periodontal disease and inhibit periodontal healing, affecting patient’s response to treatment (Table 2). In a case-control study, COVID-19 is significantly associated with periodontitis severity and increased gingival inflammation [49]. Furthermore, patients with a moderate form of COVID-19 had more severe forms periodontitis than those with a mild form of COVID-19 [43].
A case report of a 38-year-old woman with generalized stage III, grade C periodontitis reported abnormal postoperative bleeding after contracting COVID-19 right after periodontal surgery. This contrasts with her uneventful postoperative visits from previous periodontal surgeries. The patient was diagnosed with COVID-19 during the postoperative phase after the third periodontal surgery on the maxillary anterior sextant. Therefore, abnormal postoperative bleeding was reported to be associated with an active degree of COVID-19 [50].
In a case series of three systemically healthy patients who contracted COVID-19, these patients experienced gingival bleeding, which was not present before active signs of COVID-19. After the COVID-19 infection subsided, gingival bleeding markedly declined in these patients. This report suggested that gingival bleeding may be attributed to COVID-19 [51].

4. Inflammatory biomarkers involved in COVID-19

Inflammatory markers identified in COVID-19 included C-reactive protein (CRP), procalcitonin (PCT), IL-6, albumin, cytokines, serum amyloid A, serum ferritin, D-dimer, cardiac troponin, and renal biomarkers such as urea and creatinine [52,53,54]. The laboratory tests for infection and inflammation in COVID-19 are elevated for erythrocyte sedimentation rate (ESR), lactose dehydrogenase (LDH), leukocyte and platelet count.
The inflammatory markers positively correlated with the severity of COVID-19 included CRP [55], PCT, Interleukin 6 (IL-6) [56], and ESR. Biomarkers in COVID-19 can be helpful in the following areas: (1) early suspicion of disease; (2) confirmation and classification of disease severity; (3) framing hospital admission criteria; (4) identification of high-risk cohort; (5) framing ICU admission criteria; (6) rationalizing therapies; (7) assessing response to therapies; (8) predicting outcomes; (9) framing criteria for discharge from the ICU and hospital [55]. Interestingly, studies reporting COVID-19 biomarkers such as CRP, D-dimer, ferritin, PCT [56], N-terminal-pro-brain natriuretic peptide (NT-proBNP) [57,58], and IL-6 also found periodontal disease progression in these systemically healthy patients.

5. Inflammatory biomarkers linked with periodontitis

Periodontal inflammatory markers include serum and salivary biomarkers [59,60]. Serum biomarkers in periodontitis include TNF-α, IL1- [61,62,63], IL-6, CRP, surfactant protein-D, cortisol, osteocalcin, oncostatin M, albumin matrix metalloproteinases-3 (MMP-3), MMP-8, MMP-9 [64]. Salivary biomarkers in periodontitis include IL-6, IL1-beta, MMP-8, macrophage inflammatory protein-1 α, TNF- α, tissue inhibitor of metalloproteinases-1 (TIMP-1), receptor activator of nuclear factor kappa-Β ligand (RANKL), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine transaminase (ALT) [65]. Studies reported increasing these above-mentioned periodontal biomarkers in COVID-19 infection with associated comorbidities [66,67].

6. Inflammatory biomarkers associating periodontitis and COVID-19

Inflammatory biomarkers (Table 3) found in COVID-19 patients that have been associated with periodontal disease progression include C-reactive protein (CRP), D-dimer, ferritin, procalcitonin (PCT) and pro-brain natriuretic peptide (Pro-BNP) [57,58]. Elevation of these inflammatory COVID biomarkers could reduce extubation survival and prognosis, increase the risk of stroke and mortality, and increase the risk of developing acute respiratory disease syndrome (ARDS) and acute kidney injury [68]. HbA1C, lymphocyte, and CRP in periodontitis patients were significantly increased in the moderate form of COVID-19 compared to the mild form [43].
Bidirectionally, periodontitis biomarkers can be increased by COVID-19 infections [68]. These periodontitis biomarkers in COVID-19 patients can contribute to periodontitis disease progression in these patients [69]. These periodontitis markers include aspartate aminotransferase (AST), IL-1β [61,62], and TNF-α [70,71,72]. Elevation of these periodontitis biomarkers could increase the probing depth and clinical attachment loss, insulin resistance, acute ischemic events, autoimmune disorders, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, noninfectious uveitis, atherosclerotic lesions, vascular dysfunction, and hypertension [69].

6.1. C-reactive protein

CRP is increased in acute infections and inflammation. CRP is produced by hepatocytes. CRP is an inflammatory marker that is detected in the plasma when there is inflammation [73]. CRP is increased in COVID-19 pneumonia [74]. Increased CRP levels in patients with COVID-19 are correlated with worse periodontal outcomes. CRP secretion commences 4–10 hours after an inflammatory stimulus, peaking at 48 hours, and has a half-life of 19 hours.
Increased CRP associated with worse outcomes may be correlated to a COVID-19-related “cytokine storm.” When evaluating a range of hematological and immunological markers, it was found that CRP was one of the markers predictive of death from COVID-19 [75]. Patients with periodontitis reported a higher risk of COVID-19 complications and a higher level of CRP [46]. There was a statistically significant link between CRP levels and the different stages of periodontitis [43].

6.2. D-dimer

D-dimer is a by-product of blood clotting. The clinical significance of D-dimer is related to pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation [59]. D-dimer is a marker for fibrin production; high D-dimer levels indicate hypercoagulability of the blood.
In a case-control study, it was reported that D-dimer levels were elevated in patients with COVID-19 infection and became significantly higher with critical illness [76]. D-dimer was also observed in higher concentrations in chronic periodontitis [77]. Similarly, COVID-19 patients with documented periodontal care had significantly lower D-dimer levels than COVID-19 patients without [40]. The D-dimer levels in periodontitis have been significantly correlated with a higher risk of COVID-19 complication [40,42,46].

6.3. Ferritin

Human ferritin is composed of a ferritin heavy chain (FTH) and a ferritin light chain (FTL). The synthesis of ferritin is regulated by nitrous oxide, glutathione, and other “reactive oxygen species.” An increased ferritin level indicates activation of the monocyte-macrophage system. The magnitude of inflammation reflected by high ferritin levels at the admission of COVID-19 patients is independently predictive of in-hospital mortality [78].

6.4. Procalcitonin

PCT is a precursor of calcitonin and has been used as a biomarker for the diagnosis of bacterial infection. PCT has shown clinical significance by providing physicians with a positive correlation between disease severity and elevated PCT serum levels in patients [79]. The mean serum PCT levels were over four times greater in severe COVID-19 patients than in moderate COVID-19 patients [80]. The PCT levels were over eight times higher in critical COVID-19 patients than in moderate COVID-19 patients. High PCT levels have been associated with high rates of severe COVID-19 infections in patients admitted to the emergency department [81].

6.5. Pro-BNP

Patients with elevated levels of NT-proBNP values have a significantly increased risk of death from COVID-19 compared to patients with lower values [82,83]. The plasma NT-proBNP values were mainly related to the severity of pneumonia [83]. The serum levels of pro-BNP were also reported to be associated with periodontitis [84,85,86,87].

7. Herpesvirus reactivation linking periodontitis and COVID-19

Herpesvirus infection and their reactivation have been reported in varying degrees of COVID-19 severity. Viral coinfection [14,88] and active herpesviruses [15] have also been reported in aggressive periodontitis.
In severe COVID-19 patients admitted to the Intensive care unit (ICU), reactivation of herpes simplex virus (HSV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpesvirus 6 (HHV-6) have been reported [89,90,91]. Covid-19 patients with severe infection had a higher rate of positive EBV DNA compared to patients with mild symptoms. The median EBV DNA levels were also significantly higher in the severe COVID-19 patients compared to the mild COVID-19 patients [92]. In a cross-sectional study of mild to severe COVID-19 patients, the patient group with EBV viremia reported more severe pneumonia than the EBV-negative group [93]. On the other hand, non-geriatric patients with severe COVID-19 presented with high prevalence of CMV-seropositivity compared to patients with mild COVID-19. Interestingly, CMV-seropositivity was not significant in older patients with COVID-19. Thus, CMV-seropositivity may be a potential risk factor for severe COVID-19 in non-geriatric individuals [94].
Herpesvirus reactivation [15] and coinfections [14,88] have been linked to aggressive forms of periodontal disease. Reactivation of these herpesviruses by COVID-19 infections may have the potential to aggravate aggressive periodontitis towards rapid attachment loss and bone loss. It may also have the potential to aggravate chronic or quiescent periodontitis towards more attachment loss and bone loss.
It is well known in medicine that viral synergistic infections potentiate one or more of the indicated viral etiologic agents.

8. Conclusion

The most important finding of this literature review is to provide evidence for the increased risk of mortality and accompanying undesirable complications from COVID-19 in patients with periodontitis. Proper periodontal management with periodontal therapy and oral health maintenance may reduce death from COVID-19 infections and complications. Therefore, it is essential to understand the bidirectional relationship between periodontitis and COVID-19 infections. Better management of COVID-19 patients with periodontitis and periodontitis patients with COVID-19 may reduce the morbidity and mortality from COVID-19.

References

  1. WHO. Coronavirus. (2021, June 14). https://www.who.int/health-topics/coronavirus#tab=tab_1 [Accessed on January 4, 2023].
  2. Ting, M.; Suzuki, J.B. SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines. 2021, 9. [Google Scholar] [CrossRef] [PubMed]
  3. Ting, M.; Suzuki, J.B. COVID-19: Current Overview on SARS-CoV-2 and the Dental Implications. Oral health 2022, July https://www.oralhealthgroup.com/features/covid-19-current-overview-on-sars-cov-2-and-the-dental-implications/.
  4. Ting, M.; Suzuki, J.B. Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. Int. J. Transl. Med. 2022, 2, 230–241. [Google Scholar] [CrossRef]
  5. Madi, M.; Abuohashish, H.M.; Attia, D.; AlQahtani, N.; Alrayes, N.; Pavlic, V.; Bhat, S.G. Association between Periodontal Disease and Comorbidities in Saudi’s Eastern Province. BioMed Res. Int. 2021, 2021, 1–9. [Google Scholar] [CrossRef] [PubMed]
  6. Ejaz, H.; Alsrhani, A.; Zafar, A.; Javed, H.; Junaid, K.; Abdalla, A.E.; Abosalif, K.O.; Ahmed, Z.; Younas, S. COVID-19 and comorbidities: Deleterious impact on infected patients. J. Infect. Public Health 2020, 13, 1833–1839. [Google Scholar] [CrossRef] [PubMed]
  7. Aguilera, E.M.; Suvan, J.; Orlandi, M.; Catalina, Q.M.; Nart, J.; D’aiuto, F. Association Between Periodontitis and Blood Pressure Highlighted in Systemically Healthy Individuals. Hypertension 2021, 77, 1765–1774. [Google Scholar] [CrossRef] [PubMed]
  8. Leong, X.-F.; Ng, C.-Y.; Badiah, B.; Das, S. Association between Hypertension and Periodontitis: Possible Mechanisms. Sci. World J. 2014, 2014, 1–11. [Google Scholar] [CrossRef] [PubMed]
  9. Stewart, R.; West, M. Increasing Evidence for an Association Between Periodontitis and Cardiovascular Disease. Circ. 2016, 133, 549–551. [Google Scholar] [CrossRef]
  10. Periodontitis. (n.d.). https://www.ada.org/resources/research/science-and-research-institute/oral-health-topics/periodontitis [Accessed on on January 4, 2023].
  11. Mehrotra N, Singh S. Periodontitis. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541126/.
  12. Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 2015, 15, 30–44. [Google Scholar] [CrossRef]
  13. Ohnishi, T.; Nakamura, T.; Shima, K.; Noguchi, K.; Chiba, N.; Matsuguchi, T. Periodontitis promotes the expression of gingival transmembrane serine protease 2 (TMPRSS2), a priming protease for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J. Oral Biosci. 2022, 64, 229–236. [Google Scholar] [CrossRef]
  14. Slots, J. Herpesviral-bacterial interactions in periodontal diseases. Periodontol 2000. 2010, 52, 117–40. [Google Scholar] [CrossRef]
  15. Ting, M.; Contreras, A.; Slots, J. Herpesviruses in localized juvenile periodontitis. J. Periodontal Res. 2000, 35, 17–25. [Google Scholar] [CrossRef] [PubMed]
  16. Ejaz, H.; Alsrhani, A.; Zafar, A.; Javed, H.; Junaid, K.; Abdalla, A.E.; Abosalif, K.O.; Ahmed, Z.; Younas, S. COVID-19 and comorbidities: Deleterious impact on infected patients. J. Infect. Public Heal. 2020, 13, 1833–1839. [Google Scholar] [CrossRef] [PubMed]
  17. Mancini, L.; Quinzi, V.; Mummolo, S.; Marzo, G.; Marchetti, E. Angiotensin-Converting Enzyme 2 as a Possible Correlation between COVID-19 and Periodontal Disease. Appl. Sci. 2020, 10, 6224. [Google Scholar] [CrossRef]
  18. Takahashi, Y.; Watanabe, N.; Kamio, N.; Yokoe, S.; Suzuki, R.; Sato, S.; Iinuma, T.; Imai, K. Expression of the SARS-CoV-2 Receptor ACE2 and Proinflammatory Cytokines Induced by the Periodontopathic Bacterium Fusobacterium nucleatum in Human Respiratory Epithelial Cells. Int. J. Mol. Sci. 2021, 22, 1352. [Google Scholar] [CrossRef] [PubMed]
  19. To, K.K.-W.; Tsang, O.T.-Y.; Yip, C.C.-Y.; Chan, K.-H.; Wu, T.-C.; Chan, J.M.-C.; Leung, W.-S.; Chik, T.S.-H.; Choi, C.Y.-C.; Kandamby, D.H.; et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin. Infect. Dis. 2020, 71, 841–843. [Google Scholar] [CrossRef] [PubMed]
  20. Guo, D.F.; Sun, Y.L.; Hamet, P.; Inagami, T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res. 2001, 11, 165–180. [Google Scholar] [CrossRef] [PubMed]
  21. Badran, Z.; Gaudin, A.; Struillou, X.; Amador, G.; Soueidan, A. Periodontal pockets: A potential reservoir for SARS-CoV-2? Med Hypotheses 2020, 143, 109907–109907. [Google Scholar] [CrossRef]
  22. Drozdzik, A. Covid-19 and SARS-CoV-2 infection in periodontology: A narrative review. J. Periodontal Res. 2022, 57, 933–941. [Google Scholar] [CrossRef]
  23. Takahashi, Y.; Watanabe, N.; Kamio, N.; Kobayashi, R.; Iinuma, T.; Imai, K. Aspiration of periodontopathic bacteria due to poor oral hygiene potentially contributes to the aggravation of COVID-19. J. Oral Sci. 2021, 63, 1–3. [Google Scholar] [CrossRef]
  24. Mahyuddin, A.P.; Kanneganti, A.; Wong, J.J.; Dimri, P.S.; Su, L.L.; Biswas, A.; Illanes, S.E.; Mattar, C.N.Z.; Huang, R.Y.; Choolani, M. Mechanisms and evidence of vertical transmission of infections in pregnancy including SARS-CoV-2s. Prenat. Diagn. 2020, 40, 1655–1670. [Google Scholar] [CrossRef]
  25. Bourgonje, A.R.; Abdulle, A.E.; Timens, W.; Hillebrands, J.L.; Navis, G.J.; Gordijn, S.J.; Bolling, M.C.; Dijkstra, G.; Voors, A.A.; Osterhaus, A.D.; et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV -2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol. 2020, 251, 228–248. [Google Scholar] [CrossRef] [PubMed]
  26. Darbani, B. The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues. Int. J. Environ. Res. Public Heal. 2020, 17, 3433. [Google Scholar] [CrossRef] [PubMed]
  27. Zhong, M.; Lin, B.; Pathak, J.L.; Gao, H.; Young, A.J.; Wang, X.; Liu, C.; Wu, K.; Liu, M.; Chen, J.-M.; et al. ACE2 and Furin Expressions in Oral Epithelial Cells Possibly Facilitate COVID-19 Infection via Respiratory and Fecal–Oral Routes. Front. Med. 2020, 7, 580796. [Google Scholar] [CrossRef] [PubMed]
  28. Sakaguchi, W.; Kubota, N.; Shimizu, T.; Saruta, J.; Fuchida, S.; Kawata, A.; Yamamoto, Y.; Sugimoto, M.; Yakeishi, M.; Tsukinoki, K. Existence of SARS-CoV-2 Entry Molecules in the Oral Cavity. Int. J. Mol. Sci. 2020, 21, 6000. [Google Scholar] [CrossRef] [PubMed]
  29. Zhao, D.; Cheng, T.; Koohi-Moghadam, M.; Wu, M.; Yu, S.Y.; Ding, X.; Pelekos, G.; Yiu, K.H.; Jin, L. Salivary ACE2 and TMPRSS2 link to periodontal status and metabolic parameters. Clin. Transl. Discov. 2022, 2. [Google Scholar] [CrossRef]
  30. Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care 2020, 24, 1–10. [Google Scholar] [CrossRef]
  31. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260–1263. [Google Scholar] [CrossRef]
  32. PASTRIAN, S. G. Presence and expression of ACE2 receptor (Target of SARS-CoV-2) in human tissues and oral cavity. Possible routes infection in oral organs. Int. J. Odontostomat., 14(4):501-507, 2020.
  33. Wu, C.; Zheng, M.; Yang, Y.; Gu, X.; Yang, K.; Li, M.; Liu, Y.; Zhang, Q.; Zhang, P.; Wang, Y.; et al. Furin: A Potential Therapeutic Target for COVID-19. iScience 2020, 23, 101642–101642. [Google Scholar] [CrossRef]
  34. Ma Y, Hung Y, Wang T, Xiang AP, Huang W. ACE2 shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry. ChinaXiv. (2020) 202002.00082. [CrossRef]
  35. Xin L, GuangYou D, Wei Z, Jinsong S, JiaYuan C, Gao S, et al. A furin cleavage site was discovered in the S protein of the 2019 novel coronavirus. Chin J Bioinformatics. (2020) 18:103–08. [CrossRef]
  36. Mancini, L.; Americo, L.M.; Pizzolante, T.; Donati, R.; Marchetti, E. Impact of COVID-19 on Periodontitis and Peri-Implantitis: A Narrative Review. Front. Oral Heal. 2022, 3, 822824. [Google Scholar] [CrossRef]
  37. Wu, C.; Zheng, M.; Yang, Y.; Gu, X.; Yang, K.; Li, M.; Liu, Y.; Zhang, Q.; Zhang, P.; Wang, Y.; et al. Furin: A Potential Therapeutic Target for COVID-19. iScience 2020, 23, 101642–101642. [Google Scholar] [CrossRef]
  38. Bertolini, M.; Pita, A.; Koo, S.; Cardenas, A.; Meethil, A. Periodontal Disease in the COVID-19 Era: Potential Reservoir and Increased Risk for SARS-CoV-2. 2020, 20. 20. [CrossRef]
  39. Alnomay, N.; Alolayan, L.; Aljohani, R.; Almashouf, R.; Alharbi, G. Association between periodontitis and COVID-19 severity in a tertiary hospital: A retrospective cohort study. Saudi Dent. J. 2022, 34, 623–628. [Google Scholar] [CrossRef] [PubMed]
  40. Said, K.N.; Al-Momani, A.M.; Almaseeh, J.A.; Marouf, N.; Shatta, A.; Al-Abdulla, J.; Alaji, S.; Daas, H.; Tharupeedikayil, S.S.; Chinta, V.R.; et al. Association of periodontal therapy, with inflammatory biomarkers and complications in COVID-19 patients: a case control study. Clin. Oral Investig. 2022, 26, 6721–6732. [Google Scholar] [CrossRef] [PubMed]
  41. Costa, C.A.; Vilela, A.C.S.; Oliveira, S.A.; Gomes, T.D.; Andrade, A.A.C.; Leles, C.R.; Costa, N.L. Poor oral health status and adverse COVID-19 outcomes: A preliminary study in hospitalized patients. J. Periodontol. 2022, 93, 1889–1901. [Google Scholar] [CrossRef] [PubMed]
  42. Gupta, S.; Mohindra, R.; Singla, M.; Khera, S.; Sahni, V.; Kanta, P.; Soni, R.K.; Kumar, A.; Gauba, K.; Goyal, K.; et al. The clinical association between Periodontitis and COVID-19. Clin. Oral Investig. 2021, 26, 1361–1374. [Google Scholar] [CrossRef] [PubMed]
  43. Gambhir, R.; Kaur, A.; Sandhu, H.; Sarwal, A.; Bhagat, S.; Dodwad, R.; Singh, G. Assessment of correlation of COVID-19 infection and periodontitis- A comparative study. J. Fam. Med. Prim. Care 2022, 11, 1913–1917. [Google Scholar] [CrossRef] [PubMed]
  44. Mishra, S.; Gupta, V.; Rahman, W.; Gazala, M.P.; Anil, S. Association between Periodontitis and COVID-19 Based on Severity Scores of HRCT Chest Scans. Dent. J. 2022, 10, 106. [Google Scholar] [CrossRef] [PubMed]
  45. Baganet-Cobas Y, Chaple-Gil AM, Caballero-Guerra Y, Chávez-Valdez D. Self-reported periodontal disease, dental loss and COVID-19 in older adults. Revista Cubana de Medicina Militar, 2022 Retrieved , January 4, 2023, from https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1408807.
  46. Marouf, N.; Cai, W.; Said, K.N.; Daas, H.; Diab, H.; Chinta, V.R.; Hssain, A.A.; Nicolau, B.; Sanz, M.; Tamimi, F. Association between periodontitis and severity of COVID-19 infection: A case–control study. J. Clin. Periodontol. 2021, 48, 483–491. [Google Scholar] [CrossRef]
  47. Larvin, H.; Wilmott, S.; Kang, J.; Aggarwal, V.; Pavitt, S.; Wu, J. Additive Effect of Periodontal Disease and Obesity on COVID-19 Outcomes. J. Dent. Res. 2021, 100, 1228–1235. [Google Scholar] [CrossRef]
  48. Larvin, H.; Wilmott, S.; Wu, J.; Kang, J. The Impact of Periodontal Disease on Hospital Admission and Mortality During COVID-19 Pandemic. Front. Med. 2020, 7, 604980. [Google Scholar] [CrossRef]
  49. Anand, P.S.; Jadhav, P.; Kamath, K.P.; Kumar, S.R.; Vijayalaxmi, S.; Anil, S. A case-control study on the association between periodontitis and coronavirus disease (COVID-19). J. Periodontol. 2021, 93, 584–590. [Google Scholar] [CrossRef]
  50. Loukas, G.; Kosho, M.X.F.; Paraskevas, S.; Loos, B.G. Post-Operative Bleeding Complications in a Periodontitis Patient Testing Positive for COVID-19. Dent. J. 2022, 10, 110. [Google Scholar] [CrossRef] [PubMed]
  51. Manzalawi, R.; Alhmamey, K.; Abdelrasoul, M. Gingival bleeding associated with COVID-19 infection. Clin. Case Rep. 2020, 9, 294–297. [Google Scholar] [CrossRef] [PubMed]
  52. Balta, S.; Balta, I. COVID-19 and Inflammatory Markers. Curr. Vasc. Pharmacol. 2022, 20, 326–332. [Google Scholar] [CrossRef] [PubMed]
  53. Samprathi, M.; Jayashree, M. Biomarkers in COVID-19: An Up-To-Date Review. Front. Pediatr. 2021, 8, 607647. [Google Scholar] [CrossRef] [PubMed]
  54. Zeng, F.; Huang, Y.; Guo, Y.; Yin, M.; Chen, X.; Xiao, L.; Deng, G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int. J. Infect. Dis. 2020, 96, 467–474. [Google Scholar] [CrossRef] [PubMed]
  55. Parimoo, A.; Biswas, A.; Baitha, U.; Gupta, G.; Pandey, S.; Ranjan, P.; Gupta, V.; Roy, D.B.; Prakash, B.; Wig, N. Dynamics of Inflammatory Markers in Predicting Mortality in COVID-19. Cureus 2021, 13. [Google Scholar] [CrossRef] [PubMed]
  56. Marimuthu, A.; Anandhan, M.; Sundararajan, L.; Chandrasekaran, J.; Ramakrishnan, B. Utility of various inflammatory markers in predicting outcomes of hospitalized patients with COVID-19 pneumonia: A single-center experience. Lung India 2021, 38, 448–453. [Google Scholar] [CrossRef]
  57. Gao, L.; Jiang, D.; Wen, X.-S.; Cheng, X.-C.; Sun, M.; He, B.; You, L.-N.; Lei, P.; Tan, X.-W.; Qin, S.; et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir. Res. 2020, 21, 1–7. [Google Scholar] [CrossRef]
  58. Fazal, I.; Shetty, B.; Yadalam, U.; Khan, S.F.; Nambiar, M. Effectiveness of periodontal intervention on the levels of N-terminal pro-brain natriuretic peptide in chronic periodontitis patients. J. Circ. Biomarkers 2022, 11, 48–56. [Google Scholar] [CrossRef]
  59. Taba, M.; Kinney, J.; Kim, A.S.; Giannobile, W.V. Diagnostic Biomarkers for Oral and Periodontal Diseases. Dent. Clin. North Am. 2005, 49, 551–571. [Google Scholar] [CrossRef]
  60. Pavan Kumar, A.; Jagdish Reddy, G.; Raja babu, P. Biomarkers in periodontal disease. Dent. Oral Craniofacial Res. 2015, 1. [Google Scholar] [CrossRef]
  61. Kaneko, N.; Kurata, M.; Yamamoto, T.; Morikawa, S.; Masumoto, J. The role of interleukin-1 in general pathology. Inflamm. Regen. 2019, 39, 12. [Google Scholar] [CrossRef] [PubMed]
  62. Dinarello, C.A. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur. J. Immunol. 2011, 41, 1203–1217. [Google Scholar] [CrossRef] [PubMed]
  63. Hönig, J.; Rordorf-Adam, C.; Siegmund, C.; Wiedemann, W.; Erard, F. Increased interleukin-1 beta (IL-1β) concentration in gingival tissue from periodontitis patients. J. Periodontal Res. 1989, 24, 362–367. [Google Scholar] [CrossRef] [PubMed]
  64. Stathopoulou, P.G.; Buduneli, N.; Kinane, D.F. Systemic Biomarkers for Periodontitis. Curr. Oral Health Rep. 2015, 2, 218–226. [Google Scholar] [CrossRef]
  65. Cafiero, C.; Spagnuolo, G.; Marenzi, G.; Martuscelli, R.; Colamaio, M.; Leuci, S. Predictive Periodontitis: The Most Promising Salivary Biomarkers for Early Diagnosis of Periodontitis. J. Clin. Med. 2021, 10, 1488. [Google Scholar] [CrossRef]
  66. Gelzo, M.; Cacciapuoti, S.; Pinchera, B.; De Rosa, A.; Cernera, G.; Scialò, F.; Comegna, M.; Mormile, M.; Fabbrocini, G.; Parrella, R.; et al. Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci. Rep. 2022, 12, 1–7. [Google Scholar] [CrossRef]
  67. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.
  68. Taba, M.; Kinney, J.; Kim, A.S.; Giannobile, W.V. Diagnostic Biomarkers for Oral and Periodontal Diseases. Dent. Clin. North Am. 2005, 49, 551–571. [Google Scholar] [CrossRef]
  69. Battaglini, D.; Lopes-Pacheco, M.; Castro-Faria-Neto, H.C.; Pelosi, P.; Rocco, P.R.M. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. Front. Immunol. 2022, 13, 857573. [Google Scholar] [CrossRef]
  70. Popa, C.; Netea, M.G.; van Riel, P.L.C.M.; van der Meer, J.W.M.; Stalenhoef, A.F.H. The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 2007, 48, 751–762. [Google Scholar] [CrossRef]
  71. Jang, D.-I.; Lee, A.-H.; Shin, H.-Y.; Song, H.-R.; Park, J.-H.; Kang, T.-B.; Lee, S.-R.; Yang, S.-H. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int. J. Mol. Sci. 2021, 22, 2719. [Google Scholar] [CrossRef] [PubMed]
  72. Cicha, I.; Urschel, K. TNF-α in the cardiovascular system: from physiology to therapy. Int. J. Interf. Cytokine Mediat. Res. 2015, ume 7, 9–25. [Google Scholar] [CrossRef]
  73. Sarhat, E.R.; Zbaar, S.A.; Ahmed, S.E.; Ahmed, T.S.; Sarhat, T.R. Salivary biochemical variables of Liver Function in among Individuals with COVID-19 in Thi-Qar Province. Egypt. J. Chem. 2021, 65, 305–310. [Google Scholar] [CrossRef]
  74. Chen, W.; Zheng, K.I.; Liu, S.; Yan, Z.; Xu, C.; Qiao, Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann. Clin. Microbiol. Antimicrob. 2020, 19, 1–7. [Google Scholar] [CrossRef] [PubMed]
  75. Stringer, D.; Braude, P.; Myint, P.K.; Evans, L.; Collins, J.T.; Verduri, A.; Quinn, T.J.; Vilches-Moraga, A.; Stechman, M.J.; Pearce, L.; et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int. J. Epidemiol. 2021, 50, 420–429. [Google Scholar] [CrossRef] [PubMed]
  76. Yao, Y.; Cao, J.; Wang, Q.; Shi, Q.; Liu, K.; Luo, Z.; Chen, X.; Chen, S.; Yu, K.; Huang, Z.; et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J. Intensiv. Care 2020, 8, 1–11. [Google Scholar] [CrossRef] [PubMed]
  77. Dikshit, S. Fibrinogen Degradation Products and Periodontitis: Deciphering the Connection. J. Clin. Diagn. Res. 2015, 9, ZC10–2. [Google Scholar] [CrossRef]
  78. Bo Zhou, Jianqing She, Yadan Wang et al. Utility of Ferritin, Procalcitonin, and C-reactive Protein in Severe Patients with 2019 Novel Coronavirus Disease, 19 March 2020, PREPRINT (Version 1) available at Research Square. 19 March. [CrossRef]
  79. Cleland DA, Eranki AP. Procalcitonin. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539794/.
  80. Hu, R.; Han, C.; Pei, S.; Yin, M.; Chen, X. Procalcitonin levels in COVID-19 patients. International Journal of Antimicrobial Agents. 2020, 56, 106051. [Google Scholar] [CrossRef]
  81. Tong-Minh, K.; van der Does, Y.; Engelen, S.; de Jong, E.; Ramakers, C.; Gommers, D.; van Gorp, E.; Endeman, H. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect. Dis. 2022, 22, 1–9. [Google Scholar] [CrossRef]
  82. Gao L, Jiang D, Wen X-s, Cheng X-c, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respiratory Research 2020, 21, 83. [CrossRef]
  83. Wang L, Chen F, Bai L, Bai L, Huang Z, Peng Y. Association between NT-proBNP Level and the Severity of COVID-19 Pneumonia. Cardiology Research and Practice 2021, 2021, 5537275.
  84. Leira, Y.; Blanco, J. Brain natriuretic peptide serum levels in periodontitis. J. Periodontal Res. 2018, 53, 575–581. [Google Scholar] [CrossRef] [PubMed]
  85. Leira, Y.; Blanco, J. Brain natriuretic peptide serum levels in periodontitis. J. Periodontal Res. 2018, 53, 575–581. [Google Scholar] [CrossRef] [PubMed]
  86. Vijayaraj, S. , Ari, G., Rajendran, S., Mahendra, J., & Namasivayam, A. Comparison of the Serum and Salivary Levels of NT-proBNP in Systemically Healthy Subjects with Mild, Moderate and Severe Chronic Periodontitis. International Journal Of Drug Research And Dental Science 2022, 4, 40–48. [Google Scholar] [CrossRef]
  87. Molinsky RL, Yuzefpolskaya M, Norby FL, Yu B, Shah AM, Pankow JS, et al. Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure: The ARIC Study. JACC: Heart Failure. 2022, 10, 731–41. [Google Scholar]
  88. Contreras, A.; Slots, J. Herpesviruses in human periodontal disease. J. Periodontal Res. 2000, 35, 3–16. [Google Scholar] [CrossRef]
  89. Simonnet, A.; Engelmann, I.; Moreau, A.-S.; Garcia, B.; Six, S.; El Kalioubie, A.; Robriquet, L.; Hober, D.; Jourdain, M. High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect. Dis. Now 2021, 51, 296–299. [Google Scholar] [CrossRef]
  90. Saade, A.; Moratelli, G.; Azoulay, E.; Darmon, M. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect. Dis. Now 2021, 51, 676–679. [Google Scholar] [CrossRef]
  91. Zubchenko, S.; Kril, I.; Nadizhko, O.; Matsyura, O.; Chopyak, V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol. Int. 2022, 42, 1523–1530. [Google Scholar] [CrossRef]
  92. Paolucci, S.; Cassaniti, I.; Novazzi, F.; Fiorina, L.; Piralla, A.; Comolli, G.; Bruno, R.; Maserati, R.; Gulminetti, R.; Novati, S.; et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2020, 104, 315–319. [Google Scholar] [CrossRef]
  93. Im, J.H.; Nahm, C.H.; Je, Y.S.; Lee, J.-S.; Baek, J.H.; Kwon, H.Y.; Chung, M.-H.; Jang, J.-H.; Kim, J.S.; Lim, J.H.; et al. The effect of Epstein–Barr virus viremia on the progression to severe COVID-19. Medicine 2022, 101, e29027. [Google Scholar] [CrossRef] [PubMed]
  94. Weber, S.; Kehl, V.; Erber, J.; Wagner, K.I.; Jetzlsperger, A.-M.; Burrell, T.; Schober, K.; Schommers, P.; Augustin, M.; Crowell, C.S.; et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PLOS ONE 2022, 17, e0268530. [Google Scholar] [CrossRef] [PubMed]
  95. Larvin, H.; Wilmott, S.; Wu, J.; Kang, J. The Impact of Periodontal Disease on Hospital Admission and Mortality During COVID-19 Pandemic. Front. Med. 2020, 7, 604980. [Google Scholar] [CrossRef] [PubMed]
  96. Guardado-Luevanos, I.; Bologna-Molina, R.; Zepeda-Nuño, J.S.; Isiordia-Espinoza, M.; Molina-Frechero, N.; González-González, R.; Pérez-Pérez, M.; López-Verdín, S. Self-Reported Periodontal Disease and Its Association with SARS-CoV-2 Infection. Int. J. Environ. Res. Public Heal. 2022, 19, 10306. [Google Scholar] [CrossRef]
Table 1. Periodontitis associated with COVID-19 severity.
Table 1. Periodontitis associated with COVID-19 severity.
Study Type Time period Location Aim COVID-19 patients Comorbidities Blood parameters No. of patients Periodontal diagnosis Statistical significance Conclusion
Alnomay et al. 2022 [39] Retrospective cohort study Jan 2020-Jul 2021 Saudi Arabia To investigate the association between periodontitis and COVID-19 severity in the central region of Saudi Arabia COVID-19 with periodontitis

COVID-19 without periodontitis		 Diabetes, Hypertension, Obesity and other comorbidities including respiratory disorders, endocrine disorders, cardiovascular disorders, cancer, kidney dialysis or organ transplant C- reactive protein (CRP) COVID patients: 188

Periodontitis: 99

No periodontitis: 89		 Periodontitis Periodontitis associated with covid-19 complications:
Statistically significant		 Periodontitis is significantly associated with a higher risk of developing COVID-19 complications, including the need for assisted ventilation, ICU admission, and death
Cobas et al. 2022 [45] Descriptive cross-sectional study Mar 11, 2020- Mar 11, 2021 Cuba To determine the relationship between self-reported periodontal disease, dental loss and COVID-19 activity Patients infected with COVID-19 and survived Hypertension, diabetes mellitus, heart disease, chronic respiratory disease, and morbid obesity - COVID infected and survived patients: 238
 Periodontal disease and advanced periodontal disease (self-reported) Periodontal disease and advanced periodontal disease associated with the severity of COVID-19:
Not statistically significant		 Periodontal disease and the severity of COVID-19 cannot be established
Costa et al. 2022 [41] Short-term prospective study Aug 2020- Mar 2021 Brazil To assess the oral health conditions in COVID-19 patients and determine the association between oral health and disease outcomes, including the incidence of severe/critical symptoms, ICU admission Hospitalized, infected COVID-19 patients with at least one typical COVID-19 symptoms Hypertension, Obesity, Diabetes, COPD, Asthma, Cardiovascular diseases, Liver diseases, Cancer, Osteoporosis, Thyroid disease, Arthritis, HIV or other STD - 128 patients Periodontitis Periodontitis and ICU admission, severe critical symptoms and invasive ventilation: Statistically significant Periodontitis was associated with a higher occurrence of critical COVID-19 symptoms and the need for
intensive medical care and death, even when adjusted for age and presence of comorbidities
Gupta et al. 2021 [42] Cross-sectional analytical study 15 Jan 2021- 20 Feb 2021 India To assess the association of periodontal health on the complications of COVID-19 COVID-19 patients Diabetes, hypertension, pulmonary disease, chronic kidney disease, cancer,
coronary artery disease, obesity and any other comorbidities		 CRP, D-dimer, platelet count, ferritin,
glycosylated hemoglobin (HbA1c), haemoglobin (Hb), vitamin D3, neutrophil/ lymphocyte ratio (N/L), troponin,
procalcitonin and N-terminal-pro-brain natriuretic peptide
(NT-proBNP)		 82 patients Stages of periodontitis I- IV Stages of periodontitis and eventual survival, hospital admission, oxygen requirement, COVID-19 pneumonia, D-dimer, troponin and pro-BNP: Statistically significant There is a direct association between periodontal disease and
COVID-19-related outcomes
Larvin et al. 2020 [95] National, longitudinal cohort study Study recruitment: 2006- 2010

Data extraction: till August 2020		 UK To quantify the impact of periodontal disease on COVID-19 infection and related outcomes utilizing the UK Biobank data COVID-19 tested participants with self-reported history of periodontal disease

COVID-19 tested participants with no self-reported history of periodontal disease		 Cancer, hypertension, angina, cardiac arrest, diabetes, myocardial infarction, stroke, peripheral artery disease, atrial fibrillation, respiratory disease Systolic and diastolic blood pressure and resting heart rate (biomarkers) 13,253 patients Painful/ bleeding gums and loose teeth Painful/ bleeding gums and mortality for participants with COVID-19 infection: Suggestive of risk (OR= 1.71) There
was a suggestive risk of mortality for COVID-19 positive participants with periodontal disease
Larvin et al. 2021 [47] National, longitudinal cohort study Study recruitment: 2006- 2010

Data extraction: till August 2020		 UK To examine the impact of periodontal disease in obesity on COVID-19 infection and associated outcomes Participants with records of COVID-19 test result and oral health status and body mass index (BMI) ≥18.5 kg/m2 Cancer, CVD, diabetes, hypertension, inflammatory disease and respiratory disease Systolic and diastolic blood pressure and CRP 58,897 patients Periodontal disease The COVID-19 infection in individuals with periodontal disease in participants who were overweight: Suggestive of risk
(OR= 1.21)

The COVID-19 infection in individuals with periodontal disease in participants who were obese: Suggestive of risk
(OR= 1.37)		 Periodontal disease may exacerbate the effect of
obesity on hospitalization and mortality following COVID-19
infection
Guardado-Luevanos I et al. 2022 [96] Blinded case-control study Dec 2020- Jan 2021 Mexico To measure periodontal status through a previously validated test in individuals who were tested for SARS-CoV-2 infection COVID-19 positive
COVID-19 negative patients		 - - COVID positive: 117

COVID negative: 117		 Periodontal disease Periodontal disease and SARS-CoV-2 positive individuals: Medium risk
(OR= 3.3)		 Self-reported periodontal disease can be an adjuvant marker to assume
the risk of SARS-CoV-2 infection

These individuals present more symptoms at the onset of the disease
Marouf et al. 2021[46] Case-control study 27 Feb 2020- 31 Jul 2020 Qatar To estimate the extent to which periodontitis is associated with COVID-19 complications COVID-19 positive patients with and without complications Diabetes and comorbidities HbA1C, Vit-D, lymphocyte, D-dimer, CRP, WBC COVID-19 patients with complications: 40 (cases)

COVID-19 patients without complications: 528 (controls)		 Periodontitis Periodontitis and risk of having COVID-19 complications: Medium risk (OR= 6.34)

Periodontitis and risk of having eventual death: High risk (OR=17.5)

Periodontitis and risk of having ICU admission: Medium risk (OR= 5.57)

Periodontitis and risk of needing assisted ventilation: Medium risk (OR=7.31)
 Periodontitis was significantly associated with a higher risk of complications from COVID-19, including ICU admission, need for assisted ventilation and death

Increased blood levels of markers
linked with worse COVID-19 outcome were D-dimer, WBC and CRP
Mishra et al. 2022 [44] Cross-sectional study Apr 2021- Aug 2021 India To determine whether an association exists between periodontitis and COVID-19 COVID-19 positive patients Diabetes and Hypertension 294 patients Stage I-IV periodontitis Periodontitis and COVID-19 pneumonia: Statistically significant Periodontitis is associated with severe COVID-19
Said et al. 2022 [40] Case control study Mar 1, 2020- Dec 31, 2020 Qatar To test the hypothesis that a history of periodontal therapy could be associated with lower risk of COVID-19 complications Patients that experienced COVID-
19-related complications such as ICU admission, mechanical
ventilation and/or death and COVID-19 patients
that recovered without major complications		 Asthma, chronic respiratory
diseases, chronic heart disease, diabetes, dermatitis, chronic
liver disease, autoimmune diseases, solid organ transplant,
peptic ulcer, immunosuppressive conditions, cancer, chronic
kidney disease, hypertension, cerebrovascular accidents and
deep vein thrombosis		 D-dimer, C-reactive
protein (CRP), urea, creatinine, ferritin, interleukin-6 (IL-6), HbA1c, vitamin D, white blood cells (WBC) and lymphocytes		 1325 patients

(71 suffered severe COVID-19 complications)		 Periodontitis (non-treated and treated) Non-treated periodontitis and assisted ventilation: Statistically significant

Non-treated periodontitis and D-dimer and ferritin: Statistically significant		 COVID-19 patients with non-treated periodontitis (stages 2–4) were significantly more likely to need mechanical ventilation

Increased blood levels of D-dimer and ferritin
in patients with non-treated periodontitis compared
to periodontally healthy and treated periodontitis
patients could imply that periodontitis increases the
risk of COVID-19 complications
Table 2. Effects of COVID-19 on periodontitis.
Table 2. Effects of COVID-19 on periodontitis.
Study Type Time period Location Aim COVID-19 patients Comorbidities No. of patients Periodontal diagnosis Results Conclusion
Anand et al. 2021 [49] Case control study Aug 2020- Feb 2021 India To determine whether periodontitis and poor oral hygiene are associated with COVID-19 COVID-19 patients Diabetes, hypertension, neoplasia COVID-19 positive patients: 79

COVID-19 negative patients: 71		 Periodontitis COVID-19 associated with periodontitis severity: Statistically significant

COVID-19 and increased gingival inflammation: Statistically significant		 SARS-CoV-2 infection may increase the prevalence and severity of periodontitis, as well as increase gingival inflammation, and is associated with poor oral hygiene
Kaur et al. 2022 [43] Comparative study Mar 2021 India To assess the correlation of COVID-19 infection and severity of periodontitis in subjects who had a mild form of the disease as compared to subjects having a moderate form of the disease and requiring hospitalization Moderate COVID-19 patients recovering in COVID ward of the hospital

Mild COVID-19 patients recovering at home		 Diabetes COVID-19 (moderate form of COVID) patients in the COVID ward of the hospital: 58

COVID-19 (mild form of COVID) patients at home: 58		 Stages 0- 4 periodontal condition The odds of getting severe periodontal disease were 6.32 times more in subjects with moderate COVID-19 compared to mild COVID-19

Moderate form of COVID-19 and periodontal disease severity: Statistically significant

Stages 0-1 periodontal condition: The increased in HbA1C, lymphocyte and CRP of moderate compared to mild COVID-19: Statistically significant

Stages 2-4 periodontal condition: The increased in HbA1C, lymphocyte, WBC and CRP of moderate compared to mild COVID-19: Statistically significant		 Subjects with moderate form of COVID had more severe periodontitis
Loukas et al. 2022 [50] Case report Jul 2020 Netherlands To present a 38-year-old woman with generalized stage III, grade C periodontitis with a distorted post-operative blood clot formation who tested positive for COVID-19 after a periodontal surgery - No known prior comorbidities 1 Generalized stage III, grade C periodontitis with an abnormal post-operative blood clot formation Initial phase: Uneventful

6 months follow-up: periodontal tissues responded favorably

Surgical phase (1-4):
1.Upper right sextant:
Healing uneventful

2. Lower right sextant:
Healing uneventful

3.Upper anterior sextant:
Day 1: No complaints

(COVID-19 diagnosis)
Day 2: Patient reported intraoral bleeding, fever, loss of taste, and abnormal blood clots
Day 3: Bleeding noted, further suturing done
Day 4: Patient reported no further bleeding

4.Lower left posterior:
Healing uneventful

6 months follow-up:
Healing uneventful		 Abnormal postoperative bleeding
tendency was associated with an active phase of COVID-19
Manzalawi et al. 2020 [51] Case series Apr 2020- May 2020 Saudi Arabia Three patients from three different Saudi
cities who reported extensive gingival bleeding and pain preceding or coincidental with the confirmation of their COVID-19 infection		 COVID-19 patients in hospital quarantine No medical history 3 Gingival bleeding The cases reported unprecedented profuse gingival bleeding that was not present before active signs of COVID-19

After COVID-19 infection subsided, gingival bleeding markedly declined		 COVID-19 infection is associated with a heightened inflammatory reaction and clinical signs of profuse gingival bleeding
Table 3. Biomarkers found in COVID-19 and periodontal disease.
Table 3. Biomarkers found in COVID-19 and periodontal disease.
Biomarkers Area affected Clinical significance
COVID biomarkers associated with periodontal disease progression [69]
CRP Pulmonary function Reduced extubation survival
Neurological manifestation Ischemic stroke occurrence
D-dimer Pulmonary function Reduced extubation survival
Cardiovascular function Poorer prognosis
Coagulation and hemostasis Risk of mortality
Neurological manifestation Ischemic stroke occurrence
Ferritin Pulmonary function ARDS development
PCT Inflammation and infection Severity and risk of mortality
Neurological manifestation Ischemic stroke occurrence
Kidney and liver function Acute kidney injury
Pro-BNP Cardiovascular function Poorer prognosis
Periodontitis biomarkers increased by COVID-19 infections
AST [68] Periodontium Increased probing depths
Clinical attachment loss
IL-1β [61,62] Periodontium Increased probing depths
Clinical attachment loss
Immune system Autoimmune disorder
Osteoarthritis
Glucose metabolism Insulin resistance
Cardiovascular function Acute ischemic events
TNF-α [70,71,72] Periodontium Increased probing depths
Clinical attachment loss
Immune system Autoimmune disorder
Rheumatoid arthritis
Inflammatory bowel disease
Noninfectious uveitis
Cardiovascular function Atherosclerotic lesions
Vascular dysfunction
Hypertension
Glucose metabolism Insulin resistance
Lipid metabolism Formation of atherogenic plaque
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated